Neuroone Medical Technologies (NMTC) Q4 2024 earnings summary

Executive summary

• Achieved FDA 510(k) clearance for the OneRF ablation system, the first device cleared for both electrical activity reporting and ablation of nervous tissue using the same device.

• Secured a strategic distribution partnership with Zimmer Biomet, including a $3 million upfront license payment and potential milestone payments.

• Initiated commercialization of the OneRF system, with strong physician interest and successful initial patient outcomes.

• Expanded product pipeline with new indications and ongoing product development in spinal cord stimulation and drug delivery.

Financial highlights

• Fiscal 2024 product revenue increased 77% to $3.5 million from $2 million in 2023.

• Fourth quarter 2024 product revenue was $0.3 million, down from $0.7 million in the prior year due to manufacturing transition.

• Net loss for fiscal 2024 was $12.3 million, compared to $11.9 million in 2023.

• Operating expenses decreased 6% year-over-year to $13 million.

• R&D expenses fell 27% to $5.1 million for the year.

Outlook and guidance

• Fiscal 2025 revenue guidance is $8–$10 million, representing 132%–190% growth over 2024.

• Gross margin expected to improve to 47%–51% in 2025 from 31% in 2024.

• Additional revenue potential from new indications not included in current guidance.